The emergence of Multi drug resistant Pseudomonas aeruginosa (MDRPA) among intensive care unit (ICU) patients is increasingly recognized as a public health threat worldwide. This work aimed to study the occurrence of MDRPA among critically ill patients in a health care setting in Alexandria. During a 12 months period, different clinical samples (sputum, endotracheal aspirates, blood, urine, and pus) obtained from ICU patients were tested for the isolation and identification of Pseudomonas aeruginosa (P. aeruginosa) strains; that were screened for their antimicrobial susceptibility patterns using single disc diffusion method. Identified MDRPA strains were further tested for their susceptibility to polymyxin E (colistin), polymyxin B, and tigecycline. Polymerase chain reaction (PCR) assay was performed to detect VIM and IMP MBL genes. Of the 105 P. aeruginosa strains isolated from various clinical samples, 20 (19%) were found to be MDRPA, of which 16 (80%) were sensitive to each of colistin and polymyxin B, while only 5 (25%) strains were sensitive to tigecycline. PCR assay revealed that 9 (45%) strains possessed VIM MBL gene and none (0%) harbored IMP MBL gene. The occurrence of MDRPA strains among critically ill patients in this study was noticeable; with colistin and polymyxin B being effective upon the majority of identified MDRPA strains, and VIM MBL gene was found to be significantly harbored.
INTRODUCTION

Pseudomonas aeruginosa (P. aeruginosa)
is a major hospital-associated pathogen; that can cause a wide spectrum of severe infections, most notably in immunocompromised patients or those hospitalized in intensive care units (ICUs). (1) It is responsible for 10-15% of the nosocomial infections worldwide. Often these infections are hard to treat due to the natural resistance of the species, as well as its remarkable ability of acquiring further mechanisms of resistance to multiple groups of antimicrobial agents. (2, 3) The multi drug resistant P. aeruginosa (MDRPA) is on the rise and the increase in its incidence raises serious concerns. (4) A review of studies on MDR and 'pan-drug A national surveillance of 13 and Excel.
-Statistical significance was set at 5% (P < 0.05). The Z-test was done. (Table 3) .
RESULTS
In
DISCUSSION
The emergence of MDRPA in hospital acquired infections among ICU patients is increasingly recognized and is related to high morbidity and mortality. (4,23) Its prevalence has increased over the past decade and has become a major public health concern. (7, 24) The phenomenon of multi drug resistant pathogens had emerged not only in Egypt but also worldwide due to the excessive antibiotic misuse. (25, 26) The present work was conducted to study the occurrence of MDRPA among critically ill patients in ICUs. Intensive care patients create an environment for infection because of the debilitating effect of prolonged hospitalization, serious underlying disease, and compromised membrane and skin barriers following the application of invasive medical equipment ( as airway, catheters, etc) (27) Reported rates of MDRPA infection varied from 0.6-32% depending on geographic location and type of surveillance study. (28) In the present study, of the 105 isolated P. aeruginosa strains; 20 (19 %) were found to be MDRPA. Nearly similar results were reported in a university hospital in
Italy (29) , where MDRPA recorded a rate of has less activity against P. aeruginosa than it does against some of the other nonEnterobacteriaceae; (39, 40) this is in accordance with the results of this study, where only 5 (25%) strains were sensitive to tigecycline. have been assigned to the database. (42) In the present study, all the 20 identified MDRPA strains were tested for VIM and IMP MBL genes using PCR assay. Nine strains (45%) were positive for VIM MBL gene, while none of the isolates (0%) was positive for IPM MBL type, and they were found to be statistically significant ( (43) Multiple antibiotic resistance in bacterial populations is a pervasive and growing clinical problem, which is recognized as a threat to public health. Hence, there is a need to conduct area-specific monitoring studies to profile different pathogens responsible for specific infections and their resistance patterns.
Conclusions:
1) The occurrence of MDRPA strains among critically ill patients was noticeable, where they represented 19% of the isolated strains.
2) Colistin and polymyxin B were found to be active upon the majority of identified MDRPA strains, where 80% of the strains were sensitive to both of them, while tigecycline was found to be less effective as only 25% of strains were sensitive to it.
3) VIM MBL gene was significantly present among the tested MDRPA strains, where 45% were positive by PCR assay. 
RECOMMENDATION
